188 related articles for article (PubMed ID: 28969563)
1. Chemotherapeutic Drugs and Plasma Proteins: Exploring New Dimensions.
Zia MK; Siddiqui T; Ali SS; Rehman AA; Ahsan H; Khan FH
Curr Protein Pept Sci; 2018; 19(10):937-947. PubMed ID: 28969563
[TBL] [Abstract][Full Text] [Related]
2. Anticancer metallodrugs: where is the next cisplatin?
Hanif M; Hartinger CG
Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
[TBL] [Abstract][Full Text] [Related]
3. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
Lazarević T; Rilak A; Bugarčić ŽD
Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in ruthenium and platinum based supramolecular coordination complexes for antitumor therapy.
Zhang X; Liu D; Lv F; Yu B; Shen Y; Cong H
Colloids Surf B Biointerfaces; 2019 Oct; 182():110373. PubMed ID: 31376689
[TBL] [Abstract][Full Text] [Related]
5. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
Nardon C; Brustolin L; Fregona D
Future Med Chem; 2016; 8(2):211-26. PubMed ID: 26807601
[TBL] [Abstract][Full Text] [Related]
6. Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy.
Abid M; Shamsi F; Azam A
Mini Rev Med Chem; 2016; 16(10):772-86. PubMed ID: 26423699
[TBL] [Abstract][Full Text] [Related]
7. Anticancer metallotherapeutics in preclinical development.
Kaluderović GN; Paschke R
Curr Med Chem; 2011; 18(31):4738-52. PubMed ID: 21919843
[TBL] [Abstract][Full Text] [Related]
8. Metal Complexes in Cancer Treatment: Journey So Far.
Kumar Singh A; Kumar A; Singh H; Sonawane P; Pathak P; Grishina M; Pal Yadav J; Verma A; Kumar P
Chem Biodivers; 2023 Apr; 20(4):e202300061. PubMed ID: 36824028
[TBL] [Abstract][Full Text] [Related]
9. Noble metal-dithiocarbamates precious allies in the fight against cancer.
Nagy EM; Ronconi L; Nardon C; Fregona D
Mini Rev Med Chem; 2012 Oct; 12(12):1216-29. PubMed ID: 22931593
[TBL] [Abstract][Full Text] [Related]
10. Strained ruthenium complexes are potent light-activated anticancer agents.
Howerton BS; Heidary DK; Glazer EC
J Am Chem Soc; 2012 May; 134(20):8324-7. PubMed ID: 22553960
[TBL] [Abstract][Full Text] [Related]
11. The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamato complexes.
Ronconi L; Fregona D
Dalton Trans; 2009 Dec; (48):10670-80. PubMed ID: 20023894
[TBL] [Abstract][Full Text] [Related]
12. A Cytostatic Ruthenium(II)-Platinum(II) Bis(terpyridyl) Anticancer Complex That Blocks Entry into S Phase by Up-regulating p27(KIP1).
Ramu V; Gill MR; Jarman PJ; Turton D; Thomas JA; Das A; Smythe C
Chemistry; 2015 Jun; 21(25):9185-97. PubMed ID: 25950156
[TBL] [Abstract][Full Text] [Related]
13. Editorial: Anticancer Ruthenium Complexes in Drug Discovery and Medicinal Chemistry.
Thota S
Mini Rev Med Chem; 2016; 16(10):771. PubMed ID: 27161007
[No Abstract] [Full Text] [Related]
14. Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?
Kenny RG; Marmion CJ
Chem Rev; 2019 Jan; 119(2):1058-1137. PubMed ID: 30640441
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of action.
Khoury A; Deo KM; Aldrich-Wright JR
J Inorg Biochem; 2020 Jun; 207():111070. PubMed ID: 32299045
[TBL] [Abstract][Full Text] [Related]
16. Interaction with Blood Proteins of a Ruthenium(II) Nitrofuryl Semicarbazone Complex: Effect on the Antitumoral Activity.
Demoro B; Bento-Oliveira A; Marques F; Costa Pessoa J; Otero L; Gambino D; F M de Almeida R; Tomaz AI
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394747
[TBL] [Abstract][Full Text] [Related]
17. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy.
Makovec T
Radiol Oncol; 2019 Mar; 53(2):148-158. PubMed ID: 30956230
[TBL] [Abstract][Full Text] [Related]
19. Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates.
Notaro A; Gasser G
Chem Soc Rev; 2017 Nov; 46(23):7317-7337. PubMed ID: 29027562
[TBL] [Abstract][Full Text] [Related]
20. The status of platinum anticancer drugs in the clinic and in clinical trials.
Wheate NJ; Walker S; Craig GE; Oun R
Dalton Trans; 2010 Sep; 39(35):8113-27. PubMed ID: 20593091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
